| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Biomarkers for evaluation of clinical efficacy of multipotential neuroprotective drugs for Alzheimer’s and Parkinson’s diseases
|
Halperin, Ilan
|
|
2009
|
6 |
1 |
p. 128-140
|
artikel
|
| 2 |
Biomarkers for Evaluation of Clinical Efficacy of Multipotential Neuroprotective Drugs for Alzheimer's and Parkinson's Diseases
|
Halperin, Ilan
|
|
2009
|
6 |
1 |
p. 128-140
13 p.
|
artikel
|
| 3 |
Biomarkers for Evaluation of Clinical Efficacy of Multipotential Neuroprotective Drugs for Alzheimer's and Parkinson's Diseases
|
Halperin, Ilan
|
|
|
6 |
1 |
p. 128-140
|
artikel
|
| 4 |
Break and poster viewing
|
|
|
2009
|
6 |
1 |
p. 203-
1 p.
|
artikel
|
| 5 |
Break and poster viewing
|
|
|
|
6 |
1 |
p. 203
|
artikel
|
| 6 |
Building a better antipsychotic: Receptor targets for the treatment of multiple symptom dimensions of schizophrenia
|
Kim, Dennis H.
|
|
2009
|
6 |
1 |
p. 78-85
|
artikel
|
| 7 |
Building a Better Antipsychotic: Receptor Targets for the Treatment of Multiple Symptom Dimensions of Schizophrenia
|
Kim, Dennis H.
|
|
2009
|
6 |
1 |
p. 78-85
8 p.
|
artikel
|
| 8 |
Building a Better Antipsychotic: Receptor Targets for the Treatment of Multiple Symptom Dimensions of Schizophrenia
|
Kim, Dennis H.
|
|
|
6 |
1 |
p. 78-85
|
artikel
|
| 9 |
Contents
|
|
|
2009
|
6 |
1 |
p. A2-A3
nvt p.
|
artikel
|
| 10 |
Contents
|
|
|
|
6 |
1 |
p. A2-A3
|
artikel
|
| 11 |
Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs
|
Millan, Mark J.
|
|
2009
|
6 |
1 |
p. 53-77
|
artikel
|
| 12 |
Dual- and Triple-Acting Agents for Treating Core and Co-morbid Symptoms of Major Depression: Novel Concepts, New Drugs
|
Millan, Mark J.
|
|
2009
|
6 |
1 |
p. 53-77
25 p.
|
artikel
|
| 13 |
Dual- and Triple-Acting Agents for Treating Core and Co-morbid Symptoms of Major Depression: Novel Concepts, New Drugs
|
Millan, Mark J.
|
|
|
6 |
1 |
p. 53-77
|
artikel
|
| 14 |
Dual-target-directed drugs that block monoamine oxidase B and adenosine A2A receptors for Parkinson’s disease
|
Petzer, Jacobus P.
|
|
2009
|
6 |
1 |
p. 141-151
|
artikel
|
| 15 |
Dual-Target–Directed Drugs that Block Monoamine Oxidase B and Adenosine A 2A Receptors for Parkinson's Disease
|
Petzer, Jacobus P.
|
|
2009
|
6 |
1 |
p. 141-151
11 p.
|
artikel
|
| 16 |
Dual-Target–Directed Drugs that Block Monoamine Oxidase B and Adenosine A 2A Receptors for Parkinson's Disease
|
Petzer, Jacobus P.
|
|
|
6 |
1 |
p. 141-151
|
artikel
|
| 17 |
Editorial Board
|
|
|
2009
|
6 |
1 |
p. A1-
1 p.
|
artikel
|
| 18 |
Editorial Board
|
|
|
|
6 |
1 |
p. A1
|
artikel
|
| 19 |
Keynote Address—GINA: Public Policy, Private Protection and Implications for Huntington Disease
|
Maltby, Lewis
|
|
2009
|
6 |
1 |
p. 203-
1 p.
|
artikel
|
| 20 |
Keynote Address—GINA: Public Policy, Private Protection and Implications for Huntington Disease
|
Maltby, Lewis
|
|
|
6 |
1 |
p. 203
|
artikel
|
| 21 |
Keynote Address—The Pathway Forward for Development of New Treatments for Manifest and Premanifest Huntington Disease
|
Katz, Russell
|
|
2009
|
6 |
1 |
p. 203-
1 p.
|
artikel
|
| 22 |
Keynote Address—The Pathway Forward for Development of New Treatments for Manifest and Premanifest Huntington Disease
|
Katz, Russell
|
|
|
6 |
1 |
p. 203
|
artikel
|
| 23 |
Keynote Address—Unmet Clinical Research Needs for Persons with Pre-Manifest Huntington Disease
|
Sabine, Charles
|
|
2009
|
6 |
1 |
p. 202-
1 p.
|
artikel
|
| 24 |
Keynote Address—Unmet Clinical Research Needs for Persons with Pre-Manifest Huntington Disease
|
Sabine, Charles
|
|
|
6 |
1 |
p. 202
|
artikel
|
| 25 |
Memoquin: A multi-target-directed ligand as an innovative therapeutic opportunity for Alzheimer’s disease
|
Bolognesi, Maria Laura
|
|
2009
|
6 |
1 |
p. 152-162
|
artikel
|
| 26 |
Memoquin: A Multi-Target–Directed Ligand as an Innovative Therapeutic Opportunity for Alzheimer's Disease
|
Bolognesi, Maria Laura
|
|
2009
|
6 |
1 |
p. 152-162
11 p.
|
artikel
|
| 27 |
Memoquin: A Multi-Target–Directed Ligand as an Innovative Therapeutic Opportunity for Alzheimer's Disease
|
Bolognesi, Maria Laura
|
|
|
6 |
1 |
p. 152-162
|
artikel
|
| 28 |
Metabotropic glutamate receptors as targets for multipotential treatment of neurological disorders
|
Byrnes, Kimberly R.
|
|
2009
|
6 |
1 |
p. 94-107
|
artikel
|
| 29 |
Metabotropic Glutamate Receptors as Targets for Multipotential Treatment of Neurological Disorders
|
Byrnes, Kimberly R.
|
|
2009
|
6 |
1 |
p. 94-107
14 p.
|
artikel
|
| 30 |
Metabotropic Glutamate Receptors as Targets for Multipotential Treatment of Neurological Disorders
|
Byrnes, Kimberly R.
|
|
|
6 |
1 |
p. 94-107
|
artikel
|
| 31 |
Multifunctional actions of approved and candidate stroke drugs
|
Minnerup, Jens
|
|
2009
|
6 |
1 |
p. 43-52
|
artikel
|
| 32 |
Multifunctional Actions of Approved and Candidate Stroke Drugs
|
Minnerup, Jens
|
|
2009
|
6 |
1 |
p. 43-52
10 p.
|
artikel
|
| 33 |
Multifunctional Actions of Approved and Candidate Stroke Drugs
|
Minnerup, Jens
|
|
|
6 |
1 |
p. 43-52
|
artikel
|
| 34 |
Multifunctional drugs as neurotherapeutics
|
Schyf, Cornelis J. Van der
|
|
2009
|
6 |
1 |
p. 1-3
|
artikel
|
| 35 |
Multifunctional Drugs As Neurotherapeutics
|
Van der Schyf, Cornelis J.
|
|
2009
|
6 |
1 |
p. 1-3
3 p.
|
artikel
|
| 36 |
Multifunctional Drugs As Neurotherapeutics
|
Van der Schyf, Cornelis J.
|
|
|
6 |
1 |
p. 1-3
|
artikel
|
| 37 |
Multifunctional drugs for head injury
|
Vink, Robert
|
|
2009
|
6 |
1 |
p. 28-42
|
artikel
|
| 38 |
Multifunctional Drugs for Head Injury
|
Vink, Robert
|
|
2009
|
6 |
1 |
p. 28-42
15 p.
|
artikel
|
| 39 |
Multifunctional Drugs for Head Injury
|
Vink, Robert
|
|
|
6 |
1 |
p. 28-42
|
artikel
|
| 40 |
Multifunctional drug treatment in neurotrauma
|
Stoica, Bogdan
|
|
2009
|
6 |
1 |
p. 14-27
|
artikel
|
| 41 |
Multifunctional Drug Treatment in Neurotrauma
|
Stoica, Bogdan
|
|
2009
|
6 |
1 |
p. 14-27
14 p.
|
artikel
|
| 42 |
Multifunctional Drug Treatment in Neurotrauma
|
Stoica, Bogdan
|
|
|
6 |
1 |
p. 14-27
|
artikel
|
| 43 |
Multifunctional neuroprotective derivatives of rasagiline as anti-alzheimer’s disease drugs
|
Weinreb, Orly
|
|
2009
|
6 |
1 |
p. 163-174
|
artikel
|
| 44 |
Multifunctional Neuroprotective Derivatives of Rasagiline as Anti-Alzheimer's Disease Drugs
|
Weinreb, Orly
|
|
2009
|
6 |
1 |
p. 163-174
12 p.
|
artikel
|
| 45 |
Multifunctional Neuroprotective Derivatives of Rasagiline as Anti-Alzheimer's Disease Drugs
|
Weinreb, Orly
|
|
|
6 |
1 |
p. 163-174
|
artikel
|
| 46 |
Multifunctional pharmacotherapy: What can we learn from study of selective serotonin reuptake inhibitor augmentation of antipsychotics in negative-symptom schizophrenia?
|
Silver, Henry
|
|
2009
|
6 |
1 |
p. 86-93
|
artikel
|
| 47 |
Multifunctional Pharmacotherapy: What Can We Learn from Study of Selective Serotonin Reuptake Inhibitor Augmentation of Antipsychotics in Negative-Symptom Schizophrenia?
|
Silver, Henry
|
|
2009
|
6 |
1 |
p. 86-93
8 p.
|
artikel
|
| 48 |
Multifunctional Pharmacotherapy: What Can We Learn from Study of Selective Serotonin Reuptake Inhibitor Augmentation of Antipsychotics in Negative-Symptom Schizophrenia?
|
Silver, Henry
|
|
|
6 |
1 |
p. 86-93
|
artikel
|
| 49 |
Multifunctional receptor-directed drugs for disorders of the central nervous system
|
Buccafusco, Jerry J.
|
|
2009
|
6 |
1 |
p. 4-13
|
artikel
|
| 50 |
Multifunctional Receptor-Directed Drugs for Disorders of the Central Nervous System
|
Buccafusco, Jerry J.
|
|
2009
|
6 |
1 |
p. 4-13
10 p.
|
artikel
|
| 51 |
Multifunctional Receptor-Directed Drugs for Disorders of the Central Nervous System
|
Buccafusco, Jerry J.
|
|
|
6 |
1 |
p. 4-13
|
artikel
|
| 52 |
Novel anti-Alzheimer’s dimer bis(7)-Cognitin: Cellular and molecular mechanisms of neuroprotection through multiple targets
|
Li, Wenming
|
|
2009
|
6 |
1 |
p. 187-201
|
artikel
|
| 53 |
Novel Anti-Alzheimer's Dimer Bis(7)-Cognitin: Cellular and Molecular Mechanisms of Neuroprotection Through Multiple Targets
|
Li, Wenming
|
|
2009
|
6 |
1 |
p. 187-201
15 p.
|
artikel
|
| 54 |
Novel Anti-Alzheimer's Dimer Bis(7)-Cognitin: Cellular and Molecular Mechanisms of Neuroprotection Through Multiple Targets
|
Li, Wenming
|
|
|
6 |
1 |
p. 187-201
|
artikel
|
| 55 |
Platform Presentation—Dimebon in Mild-to-Moderate Huntington's Disease: A Multicenter, Phase 2, Randomized, Placebo-Controlled Trial (DIMOND)
|
|
|
2009
|
6 |
1 |
p. 203-
1 p.
|
artikel
|
| 56 |
Platform Presentation—Dimebon in Mild-to-Moderate Huntington's Disease: A Multicenter, Phase 2, Randomized, Placebo-Controlled Trial (DIMOND)
|
|
|
|
6 |
1 |
p. 203
|
artikel
|
| 57 |
Platform Presentation—Lifestyle Activity and the Age of Onset of Huntington Disease
|
Trembath, K.
|
|
2009
|
6 |
1 |
p. 202-
1 p.
|
artikel
|
| 58 |
Platform Presentation—Lifestyle Activity and the Age of Onset of Huntington Disease
|
Trembath, K.
|
|
|
6 |
1 |
p. 202
|
artikel
|
| 59 |
Platform Presentation—Longitudinal Structural MRI Data from PREDICT-HD: Striatal and Cortical Changes in Pre-Clinical HD
|
Aylward, E.
|
|
2009
|
6 |
1 |
p. 202-203
2 p.
|
artikel
|
| 60 |
Platform Presentation—Longitudinal Structural MRI Data from PREDICT-HD: Striatal and Cortical Changes in Pre-Clinical HD
|
Aylward, E.
|
|
|
6 |
1 |
p. 202-203
|
artikel
|
| 61 |
Platform Presentation—Loss of Striatal Dopaminergic Function and Thalamic Compensatory Mechanism During Phenocoversion of Preclinical Huntington's Disease
|
Poston, K.L.
|
|
2009
|
6 |
1 |
p. 203-
1 p.
|
artikel
|
| 62 |
Platform Presentation—Loss of Striatal Dopaminergic Function and Thalamic Compensatory Mechanism During Phenocoversion of Preclinical Huntington's Disease
|
Poston, K.L.
|
|
|
6 |
1 |
p. 203
|
artikel
|
| 63 |
Polycyclic compounds: Ideal drug scaffolds for the design of multiple mechanism drugs?
|
Schyf, Cornells J. Van der
|
|
2009
|
6 |
1 |
p. 175-186
|
artikel
|
| 64 |
Polycyclic Compounds: Ideal Drug Scaffolds for the Design of Multiple Mechanism Drugs?
|
Van der Schyf, Cornelis J.
|
|
2009
|
6 |
1 |
p. 175-186
12 p.
|
artikel
|
| 65 |
Polycyclic Compounds: Ideal Drug Scaffolds for the Design of Multiple Mechanism Drugs?
|
Van der Schyf, Cornelis J.
|
|
|
6 |
1 |
p. 175-186
|
artikel
|
| 66 |
Poster 8: A Comparison of Two Brief Cognitive Instruments in Huntington Disease (HD)
|
Corey-Bloom, J.
|
|
2009
|
6 |
1 |
p. 206-
1 p.
|
artikel
|
| 67 |
Poster 8: A Comparison of Two Brief Cognitive Instruments in Huntington Disease (HD)
|
Corey-Bloom, J.
|
|
|
6 |
1 |
p. 206
|
artikel
|
| 68 |
Poster 12: A Metabolic Network Associated with the Progression of Preclinical Huntington's Disease: Application of the Ordinal Trends Analysis to a Longitudinal PET Study
|
Tang, C.
|
|
2009
|
6 |
1 |
p. 207-208
2 p.
|
artikel
|
| 69 |
Poster 12: A Metabolic Network Associated with the Progression of Preclinical Huntington's Disease: Application of the Ordinal Trends Analysis to a Longitudinal PET Study
|
Tang, C.
|
|
|
6 |
1 |
p. 207-208
|
artikel
|
| 70 |
Poster 3: An Examination of Actual and Potential Discrimination of Individuals at Risk of Huntington's Disease: An Analysis of the RESPOND-HD Data from Australia (Site 144)
|
Goh, A.
|
|
2009
|
6 |
1 |
p. 204-205
2 p.
|
artikel
|
| 71 |
Poster 3: An Examination of Actual and Potential Discrimination of Individuals at Risk of Huntington's Disease: An Analysis of the RESPOND-HD Data from Australia (Site 144)
|
Goh, A.
|
|
|
6 |
1 |
p. 204-205
|
artikel
|
| 72 |
Poster 5: An Item Response Analysis of Depressive Symptomatology in Pre-Huntington Disease
|
Vaccarino, A.
|
|
2009
|
6 |
1 |
p. 205-
1 p.
|
artikel
|
| 73 |
Poster 5: An Item Response Analysis of Depressive Symptomatology in Pre-Huntington Disease
|
Vaccarino, A.
|
|
|
6 |
1 |
p. 205
|
artikel
|
| 74 |
Poster 16: Antidepressant Use in PREDICT-HD: Patterns of Use Relevant to “Naturalistic” Drug Studies
|
Rowe, K.
|
|
2009
|
6 |
1 |
p. 209-
1 p.
|
artikel
|
| 75 |
Poster 16: Antidepressant Use in PREDICT-HD: Patterns of Use Relevant to “Naturalistic” Drug Studies
|
Rowe, K.
|
|
|
6 |
1 |
p. 209
|
artikel
|
| 76 |
Poster 10: A Randomized, Controlled Trial of Atomoxetine for Cognitive Dysfunction in Early Huntington's Disease
|
Beglinger, L.J.
|
|
2009
|
6 |
1 |
p. 207-
1 p.
|
artikel
|
| 77 |
Poster 10: A Randomized, Controlled Trial of Atomoxetine for Cognitive Dysfunction in Early Huntington's Disease
|
Beglinger, L.J.
|
|
|
6 |
1 |
p. 207
|
artikel
|
| 78 |
Poster 19: Basal Ganglia Pathology in Preclinical and Early Symptomatic Huntington's Disease: Diffusion Tensor Imaging, Magnetic Resonance Spectroscopy, and Volumetric Measures—Which Imaging Modality Is More Sensitive?
|
Chua, P.
|
|
2009
|
6 |
1 |
p. 210-
1 p.
|
artikel
|
| 79 |
Poster 19: Basal Ganglia Pathology in Preclinical and Early Symptomatic Huntington's Disease: Diffusion Tensor Imaging, Magnetic Resonance Spectroscopy, and Volumetric Measures—Which Imaging Modality Is More Sensitive?
|
Chua, P.
|
|
|
6 |
1 |
p. 210
|
artikel
|
| 80 |
Poster 23: Characterization of Frontal Lobe Behavioral Syndromes in Huntington's Disease (HD)
|
Oelke, L.
|
|
2009
|
6 |
1 |
p. 211-
1 p.
|
artikel
|
| 81 |
Poster 23: Characterization of Frontal Lobe Behavioral Syndromes in Huntington's Disease (HD)
|
Oelke, L.
|
|
|
6 |
1 |
p. 211
|
artikel
|
| 82 |
Poster 22: Cooperative Huntington Observational Research Trial (COHORT): Baseline Mental Health Risks
|
|
|
2009
|
6 |
1 |
p. 211-
1 p.
|
artikel
|
| 83 |
Poster 22: Cooperative Huntington Observational Research Trial (COHORT): Baseline Mental Health Risks
|
|
|
|
6 |
1 |
p. 211
|
artikel
|
| 84 |
Poster 9: Corticostriatal Abnormalities in HD: A Combined Magnetic Resonance Spectroscopy and Diffusion Tensor Imaging Study
|
Weaver, K.E.
|
|
2009
|
6 |
1 |
p. 206-207
2 p.
|
artikel
|
| 85 |
Poster 9: Corticostriatal Abnormalities in HD: A Combined Magnetic Resonance Spectroscopy and Diffusion Tensor Imaging Study
|
Weaver, K.E.
|
|
|
6 |
1 |
p. 206-207
|
artikel
|
| 86 |
Poster 14: Earliest Functional Declines in Huntington's Disease
|
O'Rourke, J.F.
|
|
2009
|
6 |
1 |
p. 208-
1 p.
|
artikel
|
| 87 |
Poster 14: Earliest Functional Declines in Huntington's Disease
|
O'Rourke, J.F.
|
|
|
6 |
1 |
p. 208
|
artikel
|
| 88 |
Poster 13: Early Diagnosis of Mitochondrial Dysfunction in Huntington's Disease In Vivo
|
Conley, K.E.
|
|
2009
|
6 |
1 |
p. 208-
1 p.
|
artikel
|
| 89 |
Poster 13: Early Diagnosis of Mitochondrial Dysfunction in Huntington's Disease In Vivo
|
Conley, K.E.
|
|
|
6 |
1 |
p. 208
|
artikel
|
| 90 |
Poster 24: Expert Treatment Preferences for the Motor, Mood, and Behavioral Symptoms of Huntington's Disease
|
Veatch Goodman, L.
|
|
2009
|
6 |
1 |
p. 211-212
2 p.
|
artikel
|
| 91 |
Poster 24: Expert Treatment Preferences for the Motor, Mood, and Behavioral Symptoms of Huntington's Disease
|
Veatch Goodman, L.
|
|
|
6 |
1 |
p. 211-212
|
artikel
|
| 92 |
Poster 21: Insurance Ownership and Genetic Risk
|
Oster, E.
|
|
2009
|
6 |
1 |
p. 210-211
2 p.
|
artikel
|
| 93 |
Poster 21: Insurance Ownership and Genetic Risk
|
Oster, E.
|
|
|
6 |
1 |
p. 210-211
|
artikel
|
| 94 |
Poster 17: Lifestyle Activity and the Age of Onset of Huntington Disease
|
Trembath, K.
|
|
2009
|
6 |
1 |
p. 209-
1 p.
|
artikel
|
| 95 |
Poster 17: Lifestyle Activity and the Age of Onset of Huntington Disease
|
Trembath, K.
|
|
|
6 |
1 |
p. 209
|
artikel
|
| 96 |
Poster 7: Memory for Temporal Sequences for the Early Detection of Cognitive Changes in Preclinical Huntington's Disease
|
Pirogovsky, E.
|
|
2009
|
6 |
1 |
p. 206-
1 p.
|
artikel
|
| 97 |
Poster 7: Memory for Temporal Sequences for the Early Detection of Cognitive Changes in Preclinical Huntington's Disease
|
Pirogovsky, E.
|
|
|
6 |
1 |
p. 206
|
artikel
|
| 98 |
Poster 11: Motor Symptom–Related Metabolic Network in Huntington's Disease
|
Feigin, A.
|
|
2009
|
6 |
1 |
p. 207-
1 p.
|
artikel
|
| 99 |
Poster 11: Motor Symptom–Related Metabolic Network in Huntington's Disease
|
Feigin, A.
|
|
|
6 |
1 |
p. 207
|
artikel
|
| 100 |
Poster 20: Music, Meditation, and Huntington's Disease
|
Pugliese, M.
|
|
2009
|
6 |
1 |
p. 210-
1 p.
|
artikel
|
| 101 |
Poster 20: Music, Meditation, and Huntington's Disease
|
Pugliese, M.
|
|
|
6 |
1 |
p. 210
|
artikel
|
| 102 |
Poster 15: Predicting Cognitive Decline: Another Method for Stratifying Samples?
|
Duff, K.
|
|
2009
|
6 |
1 |
p. 208-209
2 p.
|
artikel
|
| 103 |
Poster 15: Predicting Cognitive Decline: Another Method for Stratifying Samples?
|
Duff, K.
|
|
|
6 |
1 |
p. 208-209
|
artikel
|
| 104 |
Poster 1: Survey of Clinical Trial Interest and Literacy in Huntington Support Groups: Northwest Pilot Project
|
Goodman, L. Veatch
|
|
2009
|
6 |
1 |
p. 204-
1 p.
|
artikel
|
| 105 |
Poster 1: Survey of Clinical Trial Interest and Literacy in Huntington Support Groups: Northwest Pilot Project
|
Goodman, L. Veatch
|
|
|
6 |
1 |
p. 204
|
artikel
|
| 106 |
Poster 18: The Effects of Assistive Devices on Gait Measures in Huntington's Disease
|
Kloos, A.D.
|
|
2009
|
6 |
1 |
p. 209-210
2 p.
|
artikel
|
| 107 |
Poster 18: The Effects of Assistive Devices on Gait Measures in Huntington's Disease
|
Kloos, A.D.
|
|
|
6 |
1 |
p. 209-210
|
artikel
|
| 108 |
Poster 4: The Functional Rating Scale Taskforce for Pre-Huntington's Disease: An Empirically-Driven Initiative for New Scale Development
|
Evans, K.
|
|
2009
|
6 |
1 |
p. 205-
1 p.
|
artikel
|
| 109 |
Poster 4: The Functional Rating Scale Taskforce for Pre-Huntington's Disease: An Empirically-Driven Initiative for New Scale Development
|
Evans, K.
|
|
|
6 |
1 |
p. 205
|
artikel
|
| 110 |
Poster 2: The Involvement of Children in COHORT
|
Quaid, K.
|
|
2009
|
6 |
1 |
p. 204-
1 p.
|
artikel
|
| 111 |
Poster 2: The Involvement of Children in COHORT
|
Quaid, K.
|
|
|
6 |
1 |
p. 204
|
artikel
|
| 112 |
Poster 6: Triglyceride-Lowering Effects of EPA in Individuals with Huntington Disease
|
Block, R.C.
|
|
2009
|
6 |
1 |
p. 205-206
2 p.
|
artikel
|
| 113 |
Poster 6: Triglyceride-Lowering Effects of EPA in Individuals with Huntington Disease
|
Block, R.C.
|
|
|
6 |
1 |
p. 205-206
|
artikel
|
| 114 |
Poster viewing
|
|
|
2009
|
6 |
1 |
p. 202-
1 p.
|
artikel
|
| 115 |
Poster viewing
|
|
|
|
6 |
1 |
p. 202
|
artikel
|
| 116 |
Second Annual Huntington Disease Clinical Research Symposium
|
Sabine, Charles
|
|
2009
|
6 |
1 |
p. 202-212
|
artikel
|
| 117 |
Therapeutic potential of erythropoietin and its structural or functional variants in the nervous system
|
Sirén, Anna-Leena
|
|
2009
|
6 |
1 |
p. 108-127
|
artikel
|
| 118 |
Therapeutic Potential of Erythropoietin and its Structural or Functional Variants in the Nervous System
|
Sirén, Anna-Leena
|
|
2009
|
6 |
1 |
p. 108-127
20 p.
|
artikel
|
| 119 |
Therapeutic Potential of Erythropoietin and its Structural or Functional Variants in the Nervous System
|
Sirén, Anna-Leena
|
|
|
6 |
1 |
p. 108-127
|
artikel
|
Tijdschrift beschrijving